MX2020013569A - Proteína novedosa con propiedades antiinflamatorias. - Google Patents

Proteína novedosa con propiedades antiinflamatorias.

Info

Publication number
MX2020013569A
MX2020013569A MX2020013569A MX2020013569A MX2020013569A MX 2020013569 A MX2020013569 A MX 2020013569A MX 2020013569 A MX2020013569 A MX 2020013569A MX 2020013569 A MX2020013569 A MX 2020013569A MX 2020013569 A MX2020013569 A MX 2020013569A
Authority
MX
Mexico
Prior art keywords
inflammatory properties
novel protein
seq
prevention
isolated
Prior art date
Application number
MX2020013569A
Other languages
English (en)
Inventor
Valerie Mary Corrigall
Gabriel Stavros Panayi
Original Assignee
Immune regulation ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1809703.0A external-priority patent/GB201809703D0/en
Priority claimed from US16/007,742 external-priority patent/US10858409B2/en
Application filed by Immune regulation ltd filed Critical Immune regulation ltd
Publication of MX2020013569A publication Critical patent/MX2020013569A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona una proteína aislada o recombinante que consiste en la secuencia de aminoácidos de acuerdo con la SEQ ID NO: 3 o SEQ ID: NO: 4 y su uso en la prevención o el tratamiento de una afección inflamatoria.
MX2020013569A 2018-06-13 2019-06-12 Proteína novedosa con propiedades antiinflamatorias. MX2020013569A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1809703.0A GB201809703D0 (en) 2018-06-13 2018-06-13 Novel protein with anti-inflammatory properties
US16/007,742 US10858409B2 (en) 2018-06-13 2018-06-13 Protein with anti-inflammatory properties
PCT/GB2019/051622 WO2019239126A1 (en) 2018-06-13 2019-06-12 Novel protein with anti-inflammatory properties

Publications (1)

Publication Number Publication Date
MX2020013569A true MX2020013569A (es) 2021-05-27

Family

ID=66999851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013569A MX2020013569A (es) 2018-06-13 2019-06-12 Proteína novedosa con propiedades antiinflamatorias.

Country Status (14)

Country Link
EP (1) EP3807303A1 (es)
JP (1) JP2021528100A (es)
KR (1) KR20210039339A (es)
CN (1) CN112888704A (es)
AU (2) AU2019285831B2 (es)
BR (1) BR112020025398A2 (es)
CA (1) CA3103370A1 (es)
CL (1) CL2020003220A1 (es)
CO (1) CO2020016749A2 (es)
IL (1) IL279350A (es)
MX (1) MX2020013569A (es)
SG (1) SG11202012363XA (es)
WO (1) WO2019239126A1 (es)
ZA (1) ZA202100115B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023187422A1 (en) 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited Compositions and their use in methods for treating intestinal inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
GB0106161D0 (en) 2001-03-13 2001-05-02 King S College London Immunomodulators
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
WO2006073446A2 (en) * 2004-04-28 2006-07-13 The Trustees Of The University Of Pennsylvania Peptide-mediated protein transduction into cells the hematopoietic lineage
EP1874331B1 (en) * 2005-04-19 2014-09-03 Kings College London Use of bip against bone loss and osteoporosis
EP2872644B1 (en) * 2012-07-12 2017-07-12 UAB Baltymas Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
KR101731908B1 (ko) * 2015-08-18 2017-05-11 서울대학교산학협력단 p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Also Published As

Publication number Publication date
ZA202100115B (en) 2022-07-27
CO2020016749A2 (es) 2021-04-08
KR20210039339A (ko) 2021-04-09
CA3103370A1 (en) 2019-12-19
CN112888704A (zh) 2021-06-01
AU2024200977A1 (en) 2024-03-07
CL2020003220A1 (es) 2021-10-01
BR112020025398A2 (pt) 2021-04-06
WO2019239126A1 (en) 2019-12-19
AU2019285831B2 (en) 2023-11-16
JP2021528100A (ja) 2021-10-21
AU2019285831A1 (en) 2021-01-28
EP3807303A1 (en) 2021-04-21
SG11202012363XA (en) 2021-01-28
IL279350A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
CL2018003322A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128)
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
NZ628126A (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
NZ711037A (en) Peptides and compositions for treatment of joint damage
EA201990298A1 (ru) Способы и композиции для лечения рака
MX2021002295A (es) Variantes de proteinas recombinantes.
MX2020009733A (es) Composiciones.
MX2021014497A (es) Peptidos.
WO2017176807A3 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MY193807A (en) T-cell receptor and uses thereof
MX2020010716A (es) Metodo para escindir de la fase solida peptidos unidos a una fase solida.
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
MY187334A (en) Xylanase
MX2017016195A (es) Variantes de il-37.
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
EP4279604A3 (en) Modified beta-galactosidase
MX2020013569A (es) Proteína novedosa con propiedades antiinflamatorias.
MX2021005416A (es) Combinación de quimioterapia con lectina de s. rolfsii recombinante.
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
MX2015009867A (es) Mutantes del factor x.
WO2019059572A3 (ko) 홍어 껍질 유래의 신규한 항균 펩타이드 및 이의 용도
WO2019036725A3 (en) PEPTIDE INHIBITORS OF TAU AGGREGATION
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.